MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma

P. de la Puente; B. Muz; A. Jin; F. Azab; M. Luderer; N. N. Salama; A. K. Azab

doi:10.1038/BCJ.2016.7

MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma

P. de la Puente, B. Muz, A. Jin, F. Azab, M. Luderer, N. N. Salama, A. K. Azab

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Article number	e399
Journal	Blood Cancer Journal
Volume	6
Issue number	2
DOIs	https://doi.org/10.1038/BCJ.2016.7
State	Published - 2016
Externally published	Yes

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1038/BCJ.2016.7

Cite this

@article{9d013d5b3f5d431d888d6e1c9cecaf12,

title = "MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma",

author = "{de la Puente}, P. and B. Muz and A. Jin and F. Azab and M. Luderer and Salama, {N. N.} and Azab, {A. K.}",

note = "Funding Information: This research was partially supported by the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) and the National Cancer Institute of the NIH under award number U54CA199092.",

year = "2016",

doi = "10.1038/BCJ.2016.7",

language = "English (US)",

volume = "6",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma

AU - de la Puente, P.

AU - Muz, B.

AU - Jin, A.

AU - Azab, F.

AU - Luderer, M.

AU - Salama, N. N.

AU - Azab, A. K.

N1 - Funding Information: This research was partially supported by the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) and the National Cancer Institute of the NIH under award number U54CA199092.

PY - 2016

Y1 - 2016

UR - http://www.scopus.com/inward/record.url?scp=84995423367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995423367&partnerID=8YFLogxK

U2 - 10.1038/BCJ.2016.7

DO - 10.1038/BCJ.2016.7

M3 - Letter

C2 - 26918363

AN - SCOPUS:84995423367

SN - 2044-5385

VL - 6

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 2

M1 - e399

ER -

MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this